1. Introduction {#sec1}
===============

Zinc (Zn) is an essential element for cell growth, differentiation, and survival. It is a structural element of many proteins \[[@B1]\]. Zinc affects growth in children. It is known that adequate zinc levels in the body are essential for maintaining suitable levels of growth hormone and insulin-like growth factor in the body \[[@B2]\]. Impairment of zinc levels will consequently lead to growth hormone decrease. Zinc supplement is given to children on growth hormone replacement therapy. In addition, zinc is important for nucleic acid synthesis, cell division, and metabolism of lipids, proteins and carbohydrates. It is also essential in bone homeostasis and bone growth as well as in the maintenance of connective tissues. Decreased Zn may compromise growth and immune functions \[[@B2], [@B3]\].

Zn is known to be important for the integrity of the immune system, although its role and mechanism of action are not fully understood \[[@B1], [@B4]--[@B6]\]. Zn deficiency affects the adaptive immune system and results in thymus atrophy, lymphopenia, and impaired lymphocyte function \[[@B4], [@B7], [@B8]\].

Zinc deficiency is prevalent in children of developing countries where food is often vegetable-based and rarely includes animal products. Zinc is easily absorbed with animal proteins, while excess plant meals lead to decreased zinc absorption due to its binding to phytates \[[@B9], [@B10]\]. In such countries, Zn deficiency results in growth retardation, hypogonadism, and increased mortality and morbidly from infection-related diarrhea and pneumonia due to compromised immune function \[[@B4], [@B9]\].

Despite deficits of several specific micronutrients reported in children with thalassemia major, Zn studies yielded conflicting results \[[@B7], [@B11], [@B12]\]. Several factors contribute to zinc deficiency in thalassemia. One of these most important factors is chelation therapy. Chelators, namely, deferoxamine and deferiprone, may contribute to Zn deficiency in thalassemia as they tend to eliminate positive divalent ions, like iron and Zn, into urine \[[@B7], [@B13], [@B14]\]. On the other side, some studies showed no significant correlation between zinc level and short stature, serum ferritin level, desferrioxamine dose, age at first blood transfusion, and chelation therapy \[[@B7]\]. Zinc can be normal in some patients especially those who are on regular blood transfusions \[[@B7], [@B11], [@B12]\]. What is notable that these studies were performed on adequately treated patients subjects which is not the case in many thalassemia affected areas where access to treatment is not always possible.

In the present study, we aimed to assess serum Zn levels in patients with thalassemia and their siblings in a lower middle income country, namely, Pakistan (<http://data.worldbank.org/country/pakistan>), to determine whether Zn deficiency is present and, if so, if it is related to the disease per se, the use of chelation or to nutritional factors.

2. Patients and Methods {#sec2}
=======================

The present study was performed at the Children\'s Hospital of the Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan, between June 2009 and February 2012. A total of 30 patients with *β*-thalassemia major and 30 siblings were included. Parental informed consent was obtained. The following data were obtained from the patients\' clinical file records: blood transfusion history, last ferritin measurement, onset of chelation therapy and type of chelation used, and infection profile. In addition to serum Zn levels, anthropometric measures such as height, weight, and body mass index (BMI) (BMI = weight (kg)/height^2^ (m^2^) were obtained).

Sampling and processing: Three mL of peripheral venous blood was withdrawn from each patient and sibling in the early morning, three hours before having breakfast. The samples were left for 20 minutes to clot at room temperature and then centrifuged at 2000 ×g for 10 minutes, and sera were separated and put into aliquots which were stored at −70°C till they were analyzed by atomic absorption spectrometer (AAS; AA300). Zn normal values were estimated to lie between 65 and 120 *μ*g/dL \[[@B15]\].

Statistical analyses were performed by parametric single and paired *t*-test (after the run of normality test to check that data is normally distributed) and Pearson\'s correlation coefficient test. A *P* value ≤ 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

Median patient age was 4.5 years (ranging from 1 to 10.6 years) and median sibling age was 7.3 years (ranging from 1.1 to 17 years). Patients\' serum Zn ranged from 10 *μ*g/dL to 297 *μ*g/dL (median 100 *μ*g/dL), while siblings\' serum Zn ranged from 13 *μ*g/dL to 212 *μ*g/dL (median 92 *μ*g/dL) ([Figure 1](#fig1){ref-type="fig"}). There were no significant differences in Zn levels between the patients and their corresponding siblings (*P* = 0.19) on matched pair analysis ([Table 1](#tab1){ref-type="table"}). However, it was found that Zn levels were significantly correlated between patients with their corresponding siblings (*r* correlation coefficient = 0.63, *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}).

After measuring the height for age *Z*-scores for the 30 patients with thalassemia, it was found that heights ranged between −4.2 at minimum and 1.09 at maximum (median = −1.5). Height for age *Z*-scores and Zn levels did not correlate (*r* = 0.05).

For siblings, the median height for age *Z*-scores was −1.2 and ranged from −3.78 to 2.6 (median = −1.2). A comparison of patient height for age *Z*-scores with corresponding values for siblings revealed that patients\' *Z*-scores levels were significantly lower than corresponding siblings (*P* = 0.02). Correlation between the two groups was weakly positive (*r* = 0.4), and pairing between the two groups was statistically significant (*P* = 0.01).

The median patient serum ferritin level was 2065 ng/mL (range: 5475 ng/mL--81.15 ng/mL) and showed no correlation with patients\' Zn level (*P* = 0.7).

Regular chelation therapy was used by 14 patients: 7 cases were on deferasirox and 7 cases on desferrioxamine, while 16 cases received no chelation therapy. No significant difference in Zn levels was found between chelated and nonchelated groups (median zinc levels were 103.5 *μ*g/dL and 96 *μ*g/dL for chelated and nonchelated patients, respectively, *P* = 0.63). There was also no significant difference in zinc values between patients on desferrioxamine and those on deferasirox (median zinc levels were 96 *μ*g/dL and 102 *μ*g/dL for patients with desferrioxamine and deferasirox, respectively, *P* = 0.37).

Absolute lymphocytic count (ALC) ranged between 817 and 9040 microL, with a median of 3882 microL. No correlation was found between patients\' Zn values and ALC (*r* = 0.36).

4. Discussion {#sec4}
=============

Zinc is an essential element for growth and immunity. In this study we aimed to compare serum Zn levels between thalassemia patients and their healthy siblings as to assess whether a possible deficiency is influenced by the disease itself or by nutritional and familial/environmental causes.

Patients\' and siblings\' Zn median values were within the normal range (median values were 100 *μ*g/dL and 92 *μ*g/dL for patients and siblings, resp.) with no significant difference (patients\' serum Zn median value was 100 *μ*g/dL versus 92 *μ*g/dL for siblings) ([Figure 1](#fig1){ref-type="fig"}). This finding is in agreement with studies by Rea et al. (1984) \[[@B12]\] and Donma et al. (1990) \[[@B11]\] who noted that the serum Zn levels of patients with thalassemia can be higher than normal \[[@B11], [@B12]\]. Among the 30 siblings in this study, 18 were carriers for beta thalassemia and 12 were not with no significant differences between the two groups, suggesting that Zn status is not related to thalassemia---the disease itself or trait. The patients\' Zn values in this study correlated significantly with corresponding siblings (*r* correlation coefficient = 0.63, *P* \< 0.0001) ([Figure 2](#fig2){ref-type="fig"}) suggesting that Zn level was not influenced by thalassemia or its treatment \[[@B7]\], but rather seems more likely related to familial factors either genetic or nutritional/environmental \[[@B7]\].

No correlation between Zn values and growth (height for age *Z*-scores) was observed in our patients. Similar results have been found in several other studies; thus, it is assumed that a Zn deficiency is not related to short stature \[[@B7], [@B16]\]. However, in a study by Kyriakou and Skordis (2009) \[[@B17]\], the authors proposed that Zn deficiency could be a concomitant factor for growth failure among patients with thalassemia \[[@B17]\]. As patients were found to have significant lower height-for-age compared to their siblings, however there are other concomitant variables such as chronic anemia, iron overload-related endocrine problems, and impaired bone growth which play an important role \[[@B18]--[@B20]\]. In our study zinc levels did not seem to differ among siblings suggesting that Zn deficiency may not play a significant role in growth differences often observed between thalassemic children and their brothers or sisters.

It appears that elevated ferritin levels are inversely related to Zn levels so that as ferritin increases, Zn decreases. However, in this study, the correlation was not statically significant. Decreased zinc levels or increased ferritin values have been previously reported \[[@B7], [@B21]\] and might be explained by inadequacy of clinical care and proper management affecting independently both ferritin and nutritional Zn levels.

With the limitation of a small sample size, in our study chelation therapy did not seem to affect zinc levels. Deferoxamine and deferiprone have been reported to also chelate and eliminate zinc into urine, while for deferasirox, which has a lower affinity for divalent zinc, this seems not to be the case \[[@B7], [@B13], [@B14]\].

Several studies have assumed that Zn is important to maintain intact lymphocytic function and counts \[[@B4], [@B7]\]. Fraker and King (2004) \[[@B8]\] found that a Zn deficiency led to lymphopenia \[[@B8]\]. In conclusion, this study showed that patients with thalassemia do not seem to be prone to Zn deficiency. Patients\' serum Zn values correlated with their sibling suggesting that serum Zn levels are possibly more influenced by familial and environmental factors rather than by thalassemia per se or its treatment.
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###### 

\(a\) A collective table for the data of the patients: zinc level in *μ*g/dL, sex (m: male, f: female), age (in years), height (in cm), height-age *z*-score, ferritin level (in ng/mL), chelation type, and ALC (in microL). (b) A collective table for the data of the patients: zinc level in *μ*g/dL, sex (m: male, f: female), age (in years), height (in cm), and height-age *z*-score.

  Patient number   Zinc level (*μ*g/dL)   Sex   Age (years)   Height (cm)   Height-age *z*-score   Ferritin (ng/mL)   Chelation      ALC (microL)
  ---------------- ---------------------- ----- ------------- ------------- ---------------------- ------------------ -------------- --------------
  1                94                     m     2.6           84            −1.33                  694                None           6325
  2                58                     m     2.9           92            −0.97                  2527               None           6200
  3                68                     f     5.3           100           −2.29                  3004               Deferasirox    3903
  4                297                    m     2.5           92            −0.04                  785                None           3891
  5                130                    m     1             72            −2                     641                None           7956
  6                66                     m     5.5           106           −1.51                  2129               Deferoxamine   2156
  7                102                    f     2.5           91            −1                     2000               Deferasirox    8024
  8                80                     f     8.8           122           −1.57                  3513               Deferoxamine   2340
  9                109                    m     3.8           88            −4                     1551               None           7526
  10               157                    m     4.4           106           −1                     2425               Deferoxamine   3872
  11               120                    m     8.2           115           −2.31                  1502               Deferoxamine   3008
  12               74                     m     2.5           89            −1.17                  616                None           4884
  13               127                    m     5.4           105           −1.48                  3810               None           3570
  14               75                     f     4             95            −1.79                  1150               None           1700
  15               117                    f     4.6           111           0.92                   1804               Deferasirox    1218
  16               295                    m     1.9           81            −1.6                   850                None           9040
  17               88                     m     10.6          131           −1.5                   5475               Deferasirox    1160
  18               116                    f     4             95            −2                     2836               None           2813
  19               17                     m     4.7           113           1.09                   658                None           2592
  20               111                    m     5.6           109           −1.18                  2411               Deferoxamine   5002
  21               112                    m     7.1           114           −1.53                  1951               None           1353
  22               10                     m     1.6           72            −4.2                   81.15              None           817
  23               79                     m     2.2           83            −1.9                   2621               None           5490
  24               15                     f     5             110           0.14                   5036               Deferoxamine   1980
  25               97                     f     10            124           −2.32                  706                Deferasirox    4312
  26               96                     f     10.4          139           −0.32                  4487               Deferoxamine   3062
  27               120                    m     4.5           106           −0.33                  5054               None           3180
  28               105                    f     7.4           117           −1.41                  1760               Deferasirox    4260
  29               98                     m     1.3           75            −1.9                   3812               None           5535
  30               260                    m     4.4           98            −2.01                  4100               Deferasirox    3944

  Sibling number   Zinc level (*μ*g/dL)   Sex   Age (years)   Height (cm)   Height-age *z*-score   Sibling carrier status
  ---------------- ---------------------- ----- ------------- ------------- ---------------------- ------------------------
  Sibling of 1     25                     f     12.0          143           −1.23                  Not a carrier
  Sibling of 2     75                     m     5.9           128           2.62                   Carrier
  Sibling of 3     28                     f     9.4           127           −1.31                  Not a carrier
  Sibling of 4     203                    m     6.2           108           −1.85                  Not a carrier
  Sibling of 5     68                     f     11.5          136           −1.8                   Carrier
  Sibling of 6     35                     m     2.4           89            −0.48                  Carrier
  Sibling of 7     151                    f     1.1           77            0.74                   Not a carrier
  Sibling of 8     89                     m     4.1           108           0.95                   Carrier
  Sibling of 9     212                    f     8.7           117           −2.24                  Carrier
  Sibling of 10    194                    f     12.4          150           −0.53                  Carrier
  Sibling of 11    138                    m     6.9           110           −2.16                  Not a carrier
  Sibling of 12    72                     m     6.9           119           −0.41                  Carrier
  Sibling of 13    81                     m     1.5           75            −2.5                   Not a carrier
  Sibling of 14    82                     m     12.0          140           −1.26                  Carrier
  Sibling of 15    98                     f     2.6           144           −1.51                  Not a carrier
  Sibling of 16    90                     f     5.3           104           −1.39                  Carrier
  Sibling of 17    79                     f     17.0          149           −2.07                  Carrier
  Sibling of 18    98                     m     14.1          150           −1.8                   Not a carrier
  Sibling of 19    42                     f     9.0           137           0.74                   Not a carrier
  Sibling of 20    94                     f     7.5           118           −1.03                  Not a carrier
  Sibling of 21    107                    f     11.9          132           −2.7                   Carrier
  Sibling of 22    13                     m     3.2           89            −2.18                  Carrier
  Sibling of 23    96                     m     11.2          134           1.5                    Carrier
  Sibling of 24    13                     f     7.2           124           0.39                   Carrier
  Sibling of 25    113                    m     8.0           106           −3.78                  Carrier
  Sibling of 26    87                     f     2.4           90            −0.01                  Carrier
  Sibling of 27    123                    f     7.2           130           1.45                   Carrier
  Sibling of 28    114                    f     1.2           73            −1.1                   Carrier
  Sibling of 29    103                    f     9.2           140           0.98                   Not a carrier
  Sibling of 30    180                    f     12.0          138           −1.94                  Not a carrier
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